Evaluation of a novel herbal immunomodulator drug [IMOD] in treatment of experimental canine visceral leishmaniasis
IJPR-Iranian Journal of Pharmaceutical Research. 2014; 13 (4): 1357-1367
em Inglês
| IMEMR
| ID: emr-151755
ABSTRACT
Toxicity and drug resistance against pentavalent antimonials, medications of choice in treatment of leishmaniasis for more than 5 decades, have become important subjects globally. This study was a randomized, open labeled trial that was designed to determine efficacy and safety of IMOD as a novel herbal immunomodulator drug for treatment of canine visceral leishmaniasis [CVL]. Twenty healthy mongrel dogs were infected with Iranian strain of L. Infantum amastigotes and randomly divided to 5 groups with four animals for each included on I negative control [non-infected] II Glucantime[registered sign] III Glucantime[registered sign] plus IMOD [immune-chemotherapy] IV IMOD and V positive control [non-treated]. Physical examination, hematological, biochemical, serological, parasitological, pathological and imaging evaluations were performed pre-/post- interventions every month for 3 months. Comparing with control groups [IandV], immune-chemotherapy group [Glucantime[registered sign] plus IMOD] showed significantly higher efficacy in resolving the clinical signs and hematobiochemistry factors. Based on our results, using IMOD in combination with meglumine antimoniate [Glucantime[registered sign]] has significantly improved CVL than the latter drug alone. So, it seems this new herbal medicine is useful as adjuvant therapy for canine visceral leishmaniasis
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Tipo de estudo:
Ensaio Clínico Controlado
Idioma:
Inglês
Revista:
Iran. J. Pharm. Res.
Ano de publicação:
2014
Similares
MEDLINE
...
LILACS
LIS